Skip to main content
main-content

Editor's pick

03-03-2017 | Artificial pancreas systems | Hot topic review | Article

The artificial pancreas: Potential to transform diabetes care

medwireNews provides an overview of artificial pancreas systems, and talks to Professor Richard Bergenstal about their potential for treating type 1 diabetes.

01-28-2017 | Lipid-lowering drugs | Review | Article

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes

Khavandi, M., Duarte, F., Ginsberg, H.N. et al. Curr Cardiol Rep (2017) 19: 7. doi:10.1007/s11886-017-0818-1

An update on the pathophysiology of diabetic dyslipidemia, including the role of several apolipoproteins such as apoC-III, and a look forward to upcoming data on newer agents such as the PCSK9 and CETP inhibitors.

02-03-2017 | Mental health | Practical approach | Article

Diabetes Distress or Major Depressive Disorder? A Practical Approach to Diagnosing and Treating Psychological Comorbidities of Diabetes

Kreider, K.E. Diabetes Ther (2017) 8: 1. doi:10.1007/s13300-017-0231-1

A concise, evidence-based guide to the epidemiology, pathophysiology, and bi-directional relationship of diabetes and depression, with a practical, patient-centered approach to diagnosis and management.

Latest from across the site

03-21-2017 | Adolescents | Feature | Article

Adolescents: A challenging age group

Professor Moshe Phillip tells medwireNews why he believes the artificial pancreas will be of particular benefit for adolescents and young adults with type 1 diabetes.

03-21-2017 | Cardiovascular outcomes | News

Major ECG abnormalities highlight CVD risk in type 1 diabetes

Type 1 diabetes patients with major electrocardiographic abnormalities have double the risk for cardiovascular events of those with no such abnormalities, study findings indicate.

Source:

Diabetes Care 2017; Advance online publication

03-20-2017 | Sodium-glucose transporter-2 inhibitors | News

CVD-REAL extends EMPA-REG findings to real-world patients

Findings from the CVD-REAL trial show a protective effect of sodium glucose cotransporter-2 inhibitors against heart failure in real-world patients with type 2 diabetes.

Source:

American College of Cardiology 66th Annual Scientific Session; Washington, DC, USA: 17–19 March 2017

03-18-2017 | Heart failure | News

Neprilysin inhibition could improve glycemic control in diabetic HF patients

A post-hoc analysis of the PARADIGM-HF trial suggests that the inclusion of a neprilysin inhibitor in the medication of patients with heart failure and diabetes might enhance glycemic control.

Source:

Lancet Diabetes Endocrinol 2017; Advance online publication

03-17-2017 | OriginalPaper | Article

Does training of general practitioners for intensive treatment of people with screen-detected diabetes have a spillover effect on mortality and cardiovascular morbidity in ‘at risk’ individuals with normoglycaemia? Results from the ADDITION-Denmark cluster-randomised controlled trial

Simmons, R.K., Bruun, N.H., Witte, D.R. et al. Diabetologia (2017). doi:10.1007/s00125-017-4230-6

Training of general practitioners to provide target-driven intensive management of blood glucose levels and other cardiovascular risk factors showed some evidence of a spillover effect on the risk of cardiovascular disease over a 9-year period among individuals at high risk of diabetes. The effect was particularly pronounced among those at highest risk of cardiovascular disease.

03-17-2017 | Primary care | News

News in brief

Positive spillover effects from drive to improve diabetes primary care

A drive to improve the care of screen-detected diabetes patients in primary care appears to also result in better outcomes for high-risk patients without diabetes.

Meet our editorial board

Lori BerardSanjay KalraJay ShubrookProfessor John WildingCarol Wysham
image credits